medigraphic.com
Boletín Médico del Hospital Infantil de México

2005, Number 5

<< Back Next >>

Bol Med Hosp Infant Mex 2005; 62 (5)

Efficacy and safety of atomoxetine for the treatment of the attention deficit disorder in a pediatric population.

Barragán-Pérez E, Borboa-Arce E, Garza-Morales S, Hernández-Aguilar J

Language: Spanish
References: 14
Page: 339-347
PDF size: 110.29 Kb.


ABSTRACT

Introduction. Attention deficit consists of the presence of variable grades of inattention, hyperactivity and impulsivity disorder and is one of the most frequent psychopathologic disorders seen in pediatric population. Atomoxetine is a new molecule that offers a similar efficacy to other available drugs but with a broad safety for pediatric use. Objective: to establish the efficacy and safety of the atomoxetine for the treatment of the attention deficit disorder in a pediatric population.
Material and methods. Pediatric patients of both sexes, with attention deficit/hyperactivity disorder, seen in the department of neurology of the Hospital Infantil de Mexico in the period between 2003-2004 were selected, prior written informed consent by parents or guardians. The initial doses of atomoxetine were 0.5 mg/kg/day, and adjusting the doses depending on evaluation. The evaluation was made with a clinical and a functioning scale like ADHD-RS, KDSAD-S and CGI. The temporally related adverse effects were measure by anthropometry, and vitals signs.
Results. A total of 67 patients, 21 females and 46 males with a mean age of 8 years. The more frequent subtype was the combined in (54%) of the population. Twenty three percent of the patients had been previously treated for ADHD. A 78% had some type of comorbidity, the most frequent beign the defiant-oppositive disorder. The average dose of atomoxetine was 1.2 mg/kg/day, with an efficacy of 78%. The major secondary effects observed were headache, nausea and decreased of appetite, which diminished by the fourth week of treatment.
Conclusions. In these open clinical study, the atomoxetine demonstrated efficacy and safety in the control of the cardinal symptoms of ADHD in pediatric patients.


REFERENCES

  1. Menéndez I. Trastorno de déficit de atención con hiperactividad: clínica y diagnóstico. Rev Psiquiatr Psicol Niño Adolesc. 2001; 4: 92-102.

  2. Elia J, Ambrosini PJ, et al. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med. 1999; 340: 780-8.

  3. Barragán E. El niño y el adolescente con trastorno por déficit de atención, su mundo y sus soluciones. 2da ed. México: Editorial Altius; 2003.

  4. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit-hyperactivity disorder. Pediatr Clin North Am. 1999; 46: 857-75.

  5. Hechtman L. Predictors of long-term outcome in children with attention-deficit-hyperactivity disorder. Pediatr Clin North Am. 1999; 46: 1039-49.

  6. Swanson J, Castellanos FX, Murias M, et al. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol. 1998; 8: 263-71.

  7. Committee on children with disabilities and committee on drugs. Medication for children with attentional disorders. Pediatrics. 1996; 98: 301-4.

  8. Steven R. Pliszka, Lawarence L. Greenhill, et al. The Texas children’s medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood attention-deficit-hyperactivity disorder. Part I. J Am Acad Child Adolesc Psychiatry. 2000; 39: 908-26.

  9. Adesman AR, Morgan AM. Management of stimulant medications in children with attention-deficit-hyperactivity disorder. Pediatr Clin North Am. 1999; 46: 945-63.

  10. Geller B, Reising D, et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999; 38: 513-6.

  11. Simpson D, Perry CM. Atomoxetina. Pediatr Drugs. 2003; 5: 407-15.

  12. Michelson D, Douglas F, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit-hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics. 2001; 108: 83.

  13. Michelson D, Allen AJ, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry. 2002; 159: 1896-901.

  14. http://www.fda.gov/cder/drug/admisory/atomoxetina.htm




2020     |     www.medigraphic.com